Healthcare / Medical DevicesNasdaqCM
$0.30
-0.00 (-1.47%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-775861.00 · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
17/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-83.3%
↓Gross Margin
62.6%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-8.4%
FCF CAGR
—
FCF margin
-618.6%
FCF / Net income
0.63x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $523031.0 · net income $-5.1M · FCF $-3.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $523031.00 | $523031.00 | $448196.00 | $628591.00 | $679777.00 |
| Net Income | $-5.1M | $-5.1M | $-660588.00 | $-241217.00 | $83980.00 |
| EBITDA | $-5.2M | $-5.2M | $-589526.00 | $-195378.00 | $128613.00 |
| EPS | — | — | -0.05 | -0.02 | 0.01 |
| Gross Margin | 62.6% | 62.6% | 85.0% | 74.9% | 82.1% |
| Operating Margin | -987.5% | -987.5% | -147.7% | -41.1% | 11.0% |
| Net Margin | -974.7% | -974.7% | -147.4% | -38.4% | 12.4% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.04 | 0.51 | 0.39 |
| Current Ratio | 8.83 | 8.83 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.2M | $-3.2M | $-775861.00 | $-63636.00 | $-116152.00 |
| Returns | |||||
| ROE | -83.3% | -83.3% | -10.7% | -78.8% | 15.1% |
| Valuation | |||||
| P/B | 0.82 | 0.82 | 8.64 | — | — |
| Growth & Yield | |||||
| Revenue Growth | 16.7% | 16.7% | -28.7% | -7.5% | — |
| EPS Growth | — | — | -160.0% | -385.8% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-95.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → n/d
Residual
-95.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.